Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12735553 | 0.92 | CTSL (0.41) | CTSLCTSSCTSKGABRA1GABRB2 | |
| SCHEMBL12740092 | 0.92 | CTSL (0.41) | CTSLCTSSCTSKGABRA1GABRB2 | |
| SCHEMBL9563808 | 0.92 | CSNK2A1 (0.38) | GABRA1GABRB2ALOX5CSNK2A1C3AR1 | |
| SCHEMBL9563721 | 0.91 | CSNK2A1 (0.37) | GABRA1GABRB2ALOX5CSNK2A1C3AR1 | |
| SCHEMBL9494738 | 0.91 | CSNK2A1 (0.37) | GABRA1GABRB2ALOX5CSNK2A1C3AR1 | |
| SCHEMBL14766054 | 0.90 | LMNA (0.39) | CTSLCTSSCTSKC3AR1CNR2 | |
| SCHEMBL14766907 | 0.90 | LMNA (0.39) | CTSLCTSSCTSKC3AR1CNR2 | |
| SCHEMBL10301920 | 0.90 | CTSL (0.44) | CTSLCTSSCTSKGABRA1GABRB2 | |
| SCHEMBL21869910 | 0.89 | CNR2 (0.39) | CTSLCTSSCTSKCHKARET | |
| SCHEMBL1243473 | 0.88 | FFAR4 (0.40) | CTSLCTSSCTSKGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305627-B1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20120018672-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO PETROCHEMICAL CORPORATION (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | CTSL 3010/4885CTSS 1879/4885CTSK 2052/4885 |
| US-20120018672-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | ROCK2, ROCK1, LEF1 | CTSL 2692/4885CTSS 2219/4885CTSK 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.